Gene: FAM168A
Official Full Name: family with sequence similarity 168 member Aprovided by HGNC
Gene Summary: Involved in positive regulation of base-excision repair. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO17785 | FAM168A Knockout cell line (HeLa) | Human | FAM168A | 1:3~1:6 | Negative | Online Inquiry |
KO17786 | FAM168A Knockout cell line (HCT 116) | Human | FAM168A | 1:2~1:4 | Negative | Online Inquiry |
KO17787 | FAM168A Knockout cell line (HEK293) | Human | FAM168A | 1:3~1:6 | Negative | Online Inquiry |
KO17788 | FAM168A Knockout cell line (A549) | Human | FAM168A | 1:3~1:4 | Negative | Online Inquiry |
FAM168A Gene Knockout Cell Lines are genetically modified cell lines specifically designed to study the function and implications of the FAM168A gene, known for its role in DNA damage response and cellular stress. By employing advanced CRISPR/Cas9 genome editing technology, these cell lines exhibit an intentional knockout of the FAM168A gene, allowing researchers to directly observe the effects of its absence in cellular processes.
The key function of the FAM168A Gene Knockout Cell Lines revolves around their ability to mimic conditions of gene loss, providing insights into the cellular mechanisms that come into play during DNA repair and maintaining genomic stability. These engineered systems allow for in-depth analysis of the pathways affected by FAM168A, such as those involved in cancer development and response to therapy, making them invaluable tools in both fundamental and applied biological research.
Scientifically, the implications of using these knockout cell lines in research are profound. They facilitate investigations into the molecular underpinnings of diseases associated with DNA damage, such as cancer and neurodegenerative disorders, and can aid in the development of targeted therapies. Clinically, understanding the role of FAM168A can lead to new treatment strategies and predictive biomarkers for patient responses to chemotherapy.
Compared to traditional methods of gene editing, the FAM168A Gene Knockout Cell Lines offer higher specificity, reduced off-target effects, and a faster transition from gene editing to functional studies. Their robustness and reproducibility provide researchers with greater confidence in experimental outcomes, thereby enhancing the interpretation of results across various studies.
Researchers and clinicians seeking to understand the genetic basis of disease and therapeutic resilience will find great value in the FAM168A Gene Knockout Cell Lines. By utilizing these cell lines, users can push the boundaries of discovery in genetic research and novel therapeutic applications.
Our company specializes in cutting-edge biotechnological solutions, ensuring that we deliver high-quality products that meet the rigorous needs of researchers and clinicians around the globe. Our commitment to scientific excellence and innovation makes us a trusted partner in advancing health-related research initiatives.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.